1. All Products
  2. PHYTOMENADIONE (vitamin K1), 10mg/ml (2mg/0.2ml), 0.2ml amp.
Public Pricelist

PHYTOMENADIONE (vitamin K1), 10mg/ml (2mg/0.2ml), 0.2ml amp.

https://medicalguidelines.msf.org/en/node/915
https://unicat.msf.org/cat/product/11786
STD DINJPHYT2AN

Valid Article

Former Code(s): -X
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
Article is intended to be used with children (<12 years) ONLY.
10.2 - Medicines affecting coagulation
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
B02BA01
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
The product is part of at least one Kit. A kit is a collection of products (medical and/or logistic) that are needed for a certain intervention in emergency. The choice and quantity of the articles reflects the MSF protocols for this specific situation. The use of Kits allows to start an intervention without a detailed evaluation.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

PHYTOMENADIONE (vitamin K1)

Therapeutic Action

Vitamin K, anti-haemorrhagic

Indications

Prophylaxis and treatment of haemorrhagic disease of the newborn

Instructions for use

Two different presentations are available for different indications:

  • Oral: 10 mg/ml solution in 1 ml ampoule. It is recommended to give vitamin K1 (10 mg/day PO) to pregnant women on rifampicin treatment during the last two weeks of pregnancy to prevent haemorrhagic disease of the newborn.
  • Injectable (IM route): 10 mg/ml solution in 0.2 ml ampoule (= 2 mg/amp). Indicated for the prevention and treatment of haemorrhagic disease of the newborn.

Both presentations are mixed micelles solutions and are supplied with an oral dosing syringe.

Mixed micelles are composed of glycocholic acid (bile acid) and lecithin in an aqueous solution allowing the solubilisation of vitamin K and, therefore, an oral absorption equivalent to that by injection.

For this reason, both presentations can be administered either by ORAL or INJECTABLE (intramuscular) route.

Storage

Below 25°C - Protect from sunlight